Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Sees Significant Increase in Short Interest

Posted by Andrew Walz on Nov 19th, 2024

Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Free Report) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 510,500 shares, an increase of 7.9% from the October 15th total of 473,100 shares. Based on an average trading volume of 67,500 shares, the short-interest ratio is currently 7.6 days. Approximately 3.5% of the company’s stock are sold short.

Accelerate Diagnostics Stock Down 2.7 %

Shares of NASDAQ AXDX opened at $1.80 on Tuesday. Accelerate Diagnostics has a twelve month low of $0.73 and a twelve month high of $5.41. The firm has a market cap of $45.07 million, a P/E ratio of -0.63 and a beta of 0.59. The company has a 50 day moving average of $1.78 and a 200 day moving average of $1.48.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Thursday, November 14th.

Check Out Our Latest Stock Analysis on Accelerate Diagnostics

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent quarter. 17.14% of the stock is owned by hedge funds and other institutional investors.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.